Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
Diacylglycerol O-acyltransferase-1 (DGAT1) synthesises triacylglycerols, which are essential for dietary fat absorption and fat storage in humans. DGAT1 belongs to the membrane-bound O-acyltransferase superfamily. DGAT1 belongs to the membrane-bound O-acyltransferase (MBOAT) superfamily. acylation process of lipids and proteins. It remains unclear how human DGAT1 (hDGAT1) or other MBOATs in mammals MBOAT family members in mammals recognise substrates and catalyse reactions.
Structure and Expression of DGAT1
Structure of the DGAT1 complex with the substrate oleoyl coenzyme A. Structure of the coenzyme A complex. Each DGAT1 protomer has nine transmembrane helices and eight Each DGAT1 protomer has nine transmembrane helices, eight of which form a conserved structural fold, which we define as the MBOAT fold. DGAT1's MBOAT folded structure opens up a hollow chamber in the membrane that encloses the highly conserved catalytic reaction. enclosing highly conserved catalytic residues. This chamber has two separate entrances that house two substrates DGAT1 can exist in homodimeric or homotetrameric forms. Both forms have similar enzymatic activity. DGAT1's N-terminus interacts with neighbouring protomers, and these interactions are necessary for the generation of enzymatic activity.
DGAT1 is highly expressed in the intestine to promote fatty acid absorption, and it is also expressed in the testis, adipose tissue, and liver. DGAT2 is highly expressed in the liver and adipose tissue, but less so in the intestine. However, there are few studies on the expression patterns and functions of DGAT1 and DGAT2 in human cancers.
Glioma and DGAT1:
Diacylglycerol kinases (DGKs) are a family of enzymes that catalyse the conversion of diacylglycerol (DAG) to phosphatidic acid (PA). DGKs reduce DAG levels in cell membranes, limiting the function of DAG as a secondary messenger and as a precursor for phospholipid and TGs biosynthesis. In the brain, most DGKs are abundantly expressed and have subtype-specific regional distributions. Of the 10 known DGK isozymes, diacylglycerol kinase B (DGKB) is predominantly expressed in the cerebral cortex, whereas gliomas are expressed in the cerebral cortex. In contrast, gliomas are mainly located in the cerebral cortex. However, the function of DGKB in gliomas has been little studied. Diacylglycerol Acyltransferase 1 (DGAT1), catalyzes the esterification of acyl-coenzyme A (acyl-CoA).DGAT1 catalyzes the esterification of acyl-CoA (CoA) with diacylglycerol (DAG) to form TGs, up-regulated to reduce FA oxidation and protect against mitochondrial lipotoxicity. Mitochondrial lipotoxicity is prevented by storing excess FA in TGs. Since DGKB regulates the levels of DAG, a substrate of TG, it may also play an important role in gliomas. levels of DAG, a substrate of TG, it may also play an important role in the maintenance of lipid homeostasis, thereby regulating the growth of gliomas.
Figure 1. Chemical modelling illustrates the function of DGAT1 in the regulation of lipid homeostasis and the inhibition of the cytotoxic effects produced by DGAT1 on GBM cells.
DGAT1 and Intestinal Diseases
Patients deficient in DGAT1 have severe clinical features such as protein-losing enteropathy (PLE), vomiting and/or diarrhoea, fat intolerance and failure to grow and develop due to impaired fat metabolism but do well on a fat-restricted diet.The combination of PLE with diarrhoea may be the result of intestinal mucosal damage, and concomitant fat intolerance suggests that DGAT1 protects the epithelial cells from lipid-induced injury. Using dermal fibroblasts and intestinal organ tissues derived from patients, researchers found that DGAT1 mediates LD formation and that DGAT1 deficiency increases susceptibility to lipid-induced toxicity and apoptosis. However, LD formation in patient-derived DGAT1-deficient cells was not completely abolished by stimulation with the most common UFA, oleic acid (OA). To date, it has not been clarified how LD is formed in the absence of DGAT1 or by what mechanism LD protects epithelial cells from lipotoxicity.
References:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.